Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures

Phase 4 Completed 977 enrolled The University of Hong Kong National Institute of Allergy and Infectious Diseases (NIAID) · collab University of Chicago · collab

RandomizedParallel-groupTriple-blindPrevention

Summary

The aims of this vaccine trial are: (1) to measure humoral and selected cellular immune responses to repeated influenza vaccination with Flublok, including these responses' associations with age, birth year, and prior vaccination history; (2) to identify the characteristics of study participants who are vaccinated but still become infected with influenza virus ("vaccine failures") and participants who have poor immune responses to vaccination; and (3) to predict how influenza vaccinations and infections shape immunity.

Timeline

Start: 2020-10-05
Primary completion: 2025-12-31
Completion: 2025-12-31

Publications

Cowling BJ, Wong SS, Santos JJS, Touyon L, Ort JT, Ye N, Kwok NKM, Ho F, Cheng SMS, Ip DKM, Peiris M, Webby RJ, Wilson PC, Valkenburg SA, Tsang JS, Leung NHL, Hensley SE, Cobey S. Preliminary Findings From the Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE I) Study: A Randomized Controlled Trial. Clin Infect Dis. 2024 Oct 15;79(4):901-909. doi: 10.1093/cid/ciae380.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Flublok	Vaccine	180 ug	—
Subject	Flublok	Vaccine	0.5 ml	—

Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures

Summary

Timeline

Publications

Drugs

Indications